Showing results (31-40 of 202) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|August 13, 2002
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudineMounir Ait-Khaled, Chris Stone, Gillian Amphlett, et al.
European Journal of Clinical Pharmacology|August 1, 2007
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adultsNils von Hentig, Brenda Dauer, Annette Haberl, et al.
Antimicrobial Agents and Chemotherapy|April 16, 2008
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimenNils von Hentig, Pavel Kaykhin, Christoph Stephan, et al.
AIDS Research and Human Retroviruses|November 27, 2008
Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmissionMartin Stürmer, Amina Carlebach, Schlomo Staszewski, et al.
International Journal of STD & AIDS|May 19, 2005
Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wastingStephan Klauke, Harald Fischer, Armin Rieger, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 14, 2008
[No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients]Christoph Stephan, Gudrun Just-Nübling, Susanne Franck, et al.
The Journal of Antimicrobial Chemotherapy|November 5, 2005
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virusChristoph Stephan, Annemarie Berger, Amina Carlebach, et al.
Open Forum Infectious Diseases|November 2, 2016
Invasive Aspergillus Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the LiteratureJohn M Humphrey, Thomas J Walsh, Roy M Gulick
Antimicrobial Agents and Chemotherapy|June 20, 2007
Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1Jörn Lötsch, Sebastian Harder, Martin Stürmer, et al.
The Journal of Antimicrobial Chemotherapy|May 15, 2008
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factorsNils von Hentig, Errol Babacan, Tessa Lennemann, et al.
Pageof 21